CL2017000156A1 - Procedimientos para el tratamiento de paramixovirus. - Google Patents

Procedimientos para el tratamiento de paramixovirus.

Info

Publication number
CL2017000156A1
CL2017000156A1 CL2017000156A CL2017000156A CL2017000156A1 CL 2017000156 A1 CL2017000156 A1 CL 2017000156A1 CL 2017000156 A CL2017000156 A CL 2017000156A CL 2017000156 A CL2017000156 A CL 2017000156A CL 2017000156 A1 CL2017000156 A1 CL 2017000156A1
Authority
CL
Chile
Prior art keywords
compound
paramyxovirus
procedures
treatment
paramixovirus
Prior art date
Application number
CL2017000156A
Other languages
English (en)
Inventor
Sushmita Mukherjee Chanda
Qingling Zhang
John Fry
Lawrence M Blatt
Original Assignee
Alios Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alios Biopharma Inc filed Critical Alios Biopharma Inc
Publication of CL2017000156A1 publication Critical patent/CL2017000156A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

<p>USO DE 3’,5’-(2-METILPROPANOATO)-4’-C-(CLOROMETIL)-2’-DEOXI-2’-FLUORO-CITIDINA (COMPUESTO A), PARA MEJORAR O TRATAR UNA INFECCION POR PARAMIXOVIRUS, QUE COMPRENDE ADMINISTRAR EL COMPUESTO EN UNA PRIMERA DOSIS, Y ADMINISTRAR EL COMPUESTO EN MULTIPLES SEGUNDAS DOSIS SEPARADAS; Y EL USO DEL COMPUESTO A Y 4’-C-CLOROMETIL-2’-DEOXI-2’-FLUORO-5’-(TETRAHIDROGENO TRIFOSFATO)-CITIDINA, PARA INHIBIR LA REPLICACION DE UN PARAMIXOVIRUS.</p>
CL2017000156A 2014-07-22 2017-01-20 Procedimientos para el tratamiento de paramixovirus. CL2017000156A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462027719P 2014-07-22 2014-07-22

Publications (1)

Publication Number Publication Date
CL2017000156A1 true CL2017000156A1 (es) 2017-11-03

Family

ID=55163588

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000156A CL2017000156A1 (es) 2014-07-22 2017-01-20 Procedimientos para el tratamiento de paramixovirus.

Country Status (13)

Country Link
US (1) US20160022724A1 (es)
EP (1) EP3171878A4 (es)
JP (1) JP2017525681A (es)
KR (1) KR20170031231A (es)
AU (1) AU2015294343A1 (es)
BR (1) BR112017001162A2 (es)
CA (1) CA2955604A1 (es)
CL (1) CL2017000156A1 (es)
MA (1) MA40403A (es)
MX (1) MX2017000983A (es)
RU (1) RU2017105470A (es)
TW (1) TW201609104A (es)
WO (1) WO2016014398A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201610936RA (en) 2011-12-22 2017-02-27 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
US8980865B2 (en) 2011-12-22 2015-03-17 Alios Biopharma, Inc. Substituted nucleotide analogs
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US8916538B2 (en) 2012-03-21 2014-12-23 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
US9598457B2 (en) 2012-12-21 2017-03-21 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
GEP201706757B (en) 2012-12-21 2017-10-25 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
AU2014248116A1 (en) 2013-04-05 2015-11-12 Alios Biopharma, Inc. Hepatitis C viral infection treatment using a combination of compounds
EP3424938B1 (en) 2013-06-26 2020-07-22 Janssen BioPharma, Inc. 4'-azidoalkyl-substituted nucleosides, nucleotides and analogs thereof
HK1224229A1 (zh) 2013-06-26 2017-08-18 Alios Biopharma, Inc. 取代的核苷，核苷酸及其类似物
JP6562908B2 (ja) 2013-10-11 2019-08-21 ヤンセン バイオファーマ インク． 置換ヌクレオシド、置換ヌクレオチドおよびその類似体
HUE051986T2 (hu) 2014-06-24 2021-04-28 Janssen Biopharma Inc Helyettesített nukleozidok, nukleotidek és analógjaik virális fertõzés kezelésére való alkalmazásra
TN2016000566A1 (en) 2014-06-24 2018-04-04 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
JP2017523988A (ja) * 2014-08-05 2017-08-24 アリオス バイオファーマ インク． パラミクソウイルスを治療するための併用療法
HK1243714A1 (zh) 2014-10-28 2018-07-20 Alios Biopharma, Inc. 制备取代的核苷类似物的方法
MA41441A (fr) 2014-12-19 2017-12-12 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
EA036776B1 (ru) 2015-03-11 2020-12-21 Янссен Байофарма, Инк. Соединения азапиридона и способы их применения
WO2018081449A1 (en) * 2016-10-27 2018-05-03 Alios Biopharma, Inc. Methods for treating respiratory syncytial virus infection
WO2018222774A1 (en) * 2017-05-30 2018-12-06 Alios Biopharma, Inc. Methods for treating pneumoviruses
CN113462656B (zh) * 2021-03-24 2022-09-30 兰州生物制品研究所有限责任公司 一种人三型副流感病毒冷适应温度敏感株及其应用
EP4493573A1 (en) 2022-03-15 2025-01-22 Rome Therapeutics, Inc. Compounds and methods for treating disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ244102A (en) * 1991-08-26 1996-12-20 Scripps Research Inst Peptides inducing cytotoxic t lymphocyte responses against hbv antigen and their use
JPH0859508A (ja) * 1994-08-16 1996-03-05 Teijin Ltd サイトメガロウイルス網膜炎予防または治療剤
MX2012015292A (es) * 2010-06-24 2013-05-30 Gilead Sciences Inc Pirazolo[1, 5]pirimidinas en la forma de agentes antivirales.
SG10201610936RA (en) * 2011-12-22 2017-02-27 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
RS58437B1 (sr) * 2012-03-21 2019-04-30 Alios Biopharma Inc Supstituisani nukleozidi, nukleotidi i njihovi analozi

Also Published As

Publication number Publication date
KR20170031231A (ko) 2017-03-20
AU2015294343A1 (en) 2017-02-02
MX2017000983A (es) 2017-09-01
MA40403A (fr) 2017-05-31
EP3171878A4 (en) 2018-03-14
CA2955604A1 (en) 2016-01-28
BR112017001162A2 (pt) 2017-11-14
TW201609104A (zh) 2016-03-16
RU2017105470A (ru) 2018-08-22
RU2017105470A3 (es) 2019-02-28
US20160022724A1 (en) 2016-01-28
JP2017525681A (ja) 2017-09-07
WO2016014398A1 (en) 2016-01-28
EP3171878A1 (en) 2017-05-31

Similar Documents

Publication Publication Date Title
MX2024013963A (es) Un antagonista de il-4r util para el tratamiento o la prevencion del asma
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
MX2017000627A (es) Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe).
MX2022009352A (es) Sal de hemisulfato de nucleotido para el tratamiento del virus de hepatitis c.
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
GT201700167A (es) Terapias de combinación para el tratamiento de cánceres.
CR20160537A (es) Inhibidor de fosfoinosítido 3-quinasa delta para su uso medico
BR112017001162A2 (pt) métodos para tratar paramixovírus
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
BR112017004153A2 (pt) métodos para tratamento de infecções por protozoários
ECSP17059323A (es) Formulacion de combinacion de tesofensina y betabloqueante
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
MX2016002892A (es) Combinaciones de ligando de receptores sigma y aine.
AR103680A1 (es) Inhibidores selectivos de bace1
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
NI201500175A (es) Compuestos nuevos para el tratamiento del cáncer
DOP2018000049A (es) Compuestos para uso en aplicaciones antibacterianas
MX2019001577A (es) Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.
DOP2017000014A (es) Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo
MX2017010341A (es) Terapia para cancer con un parvovirus combinado con bevacizumab.